(19)
(11) EP 4 351 650 A1

(12)

(43) Date of publication:
17.04.2024 Bulletin 2024/16

(21) Application number: 22820793.2

(22) Date of filing: 02.06.2022
(51) International Patent Classification (IPC): 
A61K 47/22(2006.01)
A61K 31/22(2006.01)
 A61K 47/60(2017.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; A61K 47/55; A61K 49/0032; A61K 49/0052
(86) International application number:
PCT/US2022/031876
(87) International publication number:
WO 2022/260918 (15.12.2022 Gazette 2022/50)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 07.06.2021 US 202117340843

(71) Applicant: NanoPharmaceuticals LLC
Rensselaer, NY 12144 (US)

(72) Inventors:
  • MOUSA, Shaker
    New York 12198 (US)
  • RAJABI, Mehdi
    Albany, New York 12204 (US)
  • KARAKUS, Ozlem O.
    New York 12077 (US)

(74) Representative: Patrade A/S 
Ceresbyen 75
8000 Aarhus C
8000 Aarhus C (DK)

   


(54) COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS